Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 0.84 |
| ▸ | NPY4R | P50391 | 3/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | NPY1R | P25929 | 2/20 | 0.45 |
| ▸ | NPY2R | P49146 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21286624 | 0.96 | OPRK1 (0.81) | OPRK1NPY4ROPRM1NPY1RNPY2R | |
| SCHEMBL13290881 | 0.96 | OPRK1 (0.77) | OPRK1NPY4ROPRM1NPY1RNPY2R | |
| SCHEMBL10316475 | 0.95 | OPRK1 (0.85) | OPRK1NPY4ROPRM1NPY1RNPY2R | |
| SCHEMBL21286531 | 0.95 | OPRK1 (0.76) | OPRK1NPY4ROPRM1NPY1RNPY2R | |
| SCHEMBL18413282 | 0.95 | OPRK1 (0.83) | OPRK1NPY4ROPRM1NPY1RNPY2R | |
| SCHEMBL11932315 | 0.93 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL21286623 | 0.92 | OPRK1 (0.71) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10316418 | 0.91 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL13290867 | 0.91 | OPRK1 (0.78) | OPRK1NPY4ROPRM1NPY1RNPY2R | |
| SCHEMBL21886568 | 0.91 | OPRK1 (0.77) | OPRK1NPY4ROPRM1NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10793596-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9359399-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885NPY4R 118/4885OPRM1 5/4885 |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885NPY4R 45/4885OPRM1 4/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885NPY4R 43/4885OPRM1 3/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | OPRK1 1/4885NPY4R 118/4885OPRM1 5/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885NPY4R 29/4885OPRM1 2/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | OPRK1 2/4885NPY4R 304/4885OPRM1 7/4885 |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | OPRK1 2/4885NPY4R 304/4885OPRM1 7/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885OPRM1 814/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885OPRM1 814/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885NPY4R 118/4885OPRM1 5/4885 |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885OPRM1 814/4885 |
| US-10793596-B2 | Synthetic peptide amides | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885NPY4R 45/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.